Erlotinib Withdrawn Phase 1 Trials for Tumors, Solid Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00754104Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors